RECLAIM: A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines (clinicaltrials.gov) - Oct 14, 2026 - P3 | N=409 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting
Enrollment closed • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
|